SG11201900744SA - Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them - Google Patents

Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them

Info

Publication number
SG11201900744SA
SG11201900744SA SG11201900744SA SG11201900744SA SG11201900744SA SG 11201900744S A SG11201900744S A SG 11201900744SA SG 11201900744S A SG11201900744S A SG 11201900744SA SG 11201900744S A SG11201900744S A SG 11201900744SA SG 11201900744S A SG11201900744S A SG 11201900744SA
Authority
SG
Singapore
Prior art keywords
international
johnson
rule
methods
superfamily member
Prior art date
Application number
SG11201900744SA
Inventor
Mark Chiu
Di Zhang
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of SG11201900744SA publication Critical patent/SG11201900744SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Abstract

OX tend 0.9 OX405F2IgG1 0.8 An DX405621661 + protein G beads E 0.6 0.1 33 100 333 1000 Reagent (nghnl) Figure 111. • HEK-Blue. OX40 cells -A- HEK-Blue 0X40 cells +Raji cells 1000 Reagent (nghnl) W O 20 18/03 1400 Al 40 20 10 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 15 February 2018 (15.02.2018) WIP0 I PCT °mons °nolo III ium VIII iflo oimIE (10) International Publication Number WO 2018/031400 Al (51) International Patent Classification: C07K 16/12 (2006.01) C07K 16/40 (2006.01) CO7K 16/28 (2006.01) (21) International Application Number: PCT/US2017/045466 (22) International Filing Date: 04 August 2017 (04.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/374,347 12 August 2016 (12.08.2016) US (71) Applicant: JANSSEN BIOTECH, INC. [US/US]; 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 (US). (72) Inventors: CHIU, Mark; 1400 McKean Road, Spring House, Pennsylvania 19044 (US). ZHANG, Di; 1400 McK- ean Road, Spring House, Pennsylvania 19477 (US). (74) Agent: SHIRTZ, Joseph F. et al.; JOHNSON & JOHNSON, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: FC ENGINEERED ANTI-TNFR SUPERFAMILY MEMBER ANTIBODIES HAVING ENHANCED AGONISTIC AC- TIVITY AND METHODS OF USING THEM Figure IA (57) : The present invention relates to engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them. [Continued on next page] WO 2018/031400 Al MIDEDIMOMMIDIREIEHEIOMOEMONEMOVOIS Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))
SG11201900744SA 2016-08-12 2017-08-04 Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them SG11201900744SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662374347P 2016-08-12 2016-08-12
PCT/US2017/045466 WO2018031400A1 (en) 2016-08-12 2017-08-04 Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them

Publications (1)

Publication Number Publication Date
SG11201900744SA true SG11201900744SA (en) 2019-02-27

Family

ID=61158615

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900744SA SG11201900744SA (en) 2016-08-12 2017-08-04 Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them

Country Status (11)

Country Link
US (2) US20180044430A1 (en)
EP (1) EP3497126A4 (en)
JP (2) JP7009448B2 (en)
KR (1) KR102554331B1 (en)
CN (1) CN109843916B (en)
AU (1) AU2017308734A1 (en)
CA (1) CA3033665A1 (en)
IL (1) IL264515A (en)
MA (1) MA45941A (en)
SG (1) SG11201900744SA (en)
WO (1) WO2018031400A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9821010B2 (en) 2013-02-07 2017-11-21 The General Hospital Corporation Methods for expansion or depletion of T-regulatory cells
CA3023930A1 (en) 2016-05-13 2017-11-16 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
MD3601358T2 (en) 2017-08-03 2023-10-31 Alector Llc Anti-TREM2 antibodies and methods of use thereof
CA3074317A1 (en) * 2017-08-25 2019-02-28 Janssen Biotech, Inc. Fc.gamma.rii binding fibronectin type iii domains, their conjugates and multispecific molecules comprising them
KR20210061350A (en) * 2018-08-20 2021-05-27 더 제너럴 하스피탈 코포레이션 Antagonistic anti-tumor necrosis factor receptor superfamily polypeptide
KR20210089143A (en) * 2018-09-18 2021-07-15 메리맥 파마슈티컬즈, 인크. Anti-TNFR2 antibodies and uses thereof
RU2734432C1 (en) * 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Monoclonal antibody which specifically binds gitr
WO2021063313A1 (en) * 2019-09-30 2021-04-08 深圳市菲鹏生物制药股份有限公司 Fc variant having altered effector function and fusion protein thereof
JP2024508207A (en) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ LTBR agonists in combination therapy against cancer
AU2022263683A1 (en) 2021-04-25 2023-11-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-masp2 antibody, antigen-binding fragment thereof and medical use thereof

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE87659T1 (en) 1986-09-02 1993-04-15 Enzon Lab Inc BINDING MOLECULES WITH SINGLE POLYPEPTIDE CHAIN.
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
ATE275198T1 (en) 1991-12-02 2004-09-15 Medical Res Council PRODUCTION OF ANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES.
JP3720353B2 (en) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル Multivalent and multispecific binding proteins, their production and use
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1253942A4 (en) 2000-02-01 2004-06-16 Tanox Inc Cd40-binding apc-activating molecules
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
NZ536746A (en) 2002-06-13 2007-02-23 Crucell Holland Bv An agonistic antibody or fragment thereof that immunospecifically binds and stimulates the human OX40-receptor
KR20060052681A (en) 2003-05-23 2006-05-19 와이어쓰 Gitr ligand and gitr ligand-related molecules and antibody and uses thereof
EP1660126A1 (en) 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
CN101124245A (en) * 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
DK1866339T3 (en) 2005-03-25 2013-09-02 Gitr Inc GTR-binding molecules and their applications
US20100104564A1 (en) * 2005-03-29 2010-04-29 Genevieve Hansen Altered Antibody Fc Regions and Uses Thereof
KR101374454B1 (en) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 Methods for producing polypeptides by regulating polypeptide association
CA2609269C (en) 2005-05-26 2014-08-05 Seattle Genetics, Inc. Humanized anti-cd40 antibodies and their methods of use
DE102005028778A1 (en) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Multi-layer foil, useful for lining a flexible container, comprises a barrier layer, a stretch-poor plastic layer, an antistatic plastic layer and a layer containing a safe material for food
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
AU2007229698B9 (en) 2006-03-24 2012-11-08 Merck Patent Gmbh Engineered heterodimeric protein domains
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
ES2591281T3 (en) 2007-07-12 2016-11-25 Gitr, Inc. Combination therapies that employ GITR binding molecules
JP2010535032A (en) 2007-07-31 2010-11-18 メディミューン，エルエルシー Multispecific epitope binding proteins and uses thereof
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
SG10201604770VA (en) 2007-12-14 2016-08-30 Bristol Myers Squibb Co Binding molecules to the human ox40 receptor
JP2011507519A (en) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド Design and generation of human de novo pIX phage display library via fusion to pIX or pVII, vectors, antibodies, and methods
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US20100261620A1 (en) 2008-10-14 2010-10-14 Juan Carlos Almagro Methods of Humanizing and Affinity-Maturing Antibodies
JP2012525149A (en) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド Method for making heteromultimeric molecules
KR20170119746A (en) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 Anti-gitr antibodies
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
EP3141260B1 (en) 2009-11-30 2019-08-14 Janssen Biotech, Inc. Antibody fc mutants with ablated effector functions
SG183847A1 (en) 2010-03-04 2012-10-30 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CA2796571C (en) 2010-04-13 2019-10-29 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
NZ701825A (en) 2010-04-20 2016-06-24 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
AU2011275749C1 (en) 2010-07-09 2015-09-17 Aduro Biotech Holdings, Europe B.V. Agonistic antibody to CD27
ES2649155T3 (en) 2010-08-23 2018-01-10 Board Of Regents, The University Of Texas System Anti-OX40 antibodies and procedures for their use
NZ607710A (en) 2010-09-09 2014-11-28 Pfizer 4-1bb binding molecules
DK2635607T3 (en) 2010-11-05 2019-11-18 Zymeworks Inc STABLE HETERODIMED ANTIBODY DESIGN WITH MUTATIONS IN THE FC DOMAIN
UA117901C2 (en) 2011-07-06 2018-10-25 Ґенмаб Б.В. Antibody variants and uses thereof
EP2748199B1 (en) 2011-08-23 2019-08-28 Board of Regents, The University of Texas System Anti-ox40 antibodies and methods of using the same
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
CN109897103A (en) 2011-11-04 2019-06-18 酵活有限公司 There is the antibody design of the stabilization heterodimeric of mutation in Fc structural domain
SG10201605703TA (en) * 2012-07-06 2016-09-29 Genmab Bv Dimeric protein with triple mutations
EP2914627B1 (en) 2012-10-30 2021-04-07 Apexigen, Inc. Anti-cd40 antibodies and methods of use
KR20200134340A (en) 2013-01-10 2020-12-01 젠맵 비. 브이 Human igg1 fc region variants and uses thereof
DK2970980T3 (en) 2013-03-15 2018-10-22 Janssen Biotech Inc METHODS FOR MANAGING C-TERMINAL LYSIN, GALACTOSE AND SIALINIC ACID CONTENTS IN RECOMBINANT PROTEINS
BR112015023862A2 (en) 2013-03-18 2017-10-24 Biocerox Prod Bv isolated antibody, isolated nucleic acid molecule, vector, host cell, method of enhancing an immune response, method of treating cancer, pharmaceutical composition, and isolated agonistic antibody
EP3008090A1 (en) * 2013-06-14 2016-04-20 Bayer Pharma Aktiengesellschaft Anti-tweakr antibodies and uses thereof
MA40871A (en) * 2014-10-29 2017-09-05 Novartis Ag DIRECT EXPRESSION OF ANTIBODIES
WO2016118641A1 (en) * 2015-01-20 2016-07-28 Igm Biosciences, Inc. Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
MX2017012805A (en) * 2015-04-07 2018-04-11 Genentech Inc Antigen binding complex having agonistic activity and methods of use.
US20190144554A1 (en) 2015-12-01 2019-05-16 Genmab B.V. Anti-dr5 antibodies and methods of use thereof
SG11201900616UA (en) * 2016-08-02 2019-02-27 Visterra Inc Engineered polypeptides and uses thereof

Also Published As

Publication number Publication date
AU2017308734A1 (en) 2019-02-14
EP3497126A1 (en) 2019-06-19
CA3033665A1 (en) 2018-02-15
MA45941A (en) 2019-06-19
IL264515A (en) 2019-02-28
CN109843916B (en) 2023-10-31
KR20190038629A (en) 2019-04-08
JP7009448B2 (en) 2022-02-10
JP2019532025A (en) 2019-11-07
EP3497126A4 (en) 2020-04-08
US20180044430A1 (en) 2018-02-15
JP2022033769A (en) 2022-03-02
CN109843916A (en) 2019-06-04
KR102554331B1 (en) 2023-07-10
US11359029B2 (en) 2022-06-14
WO2018031400A1 (en) 2018-02-15
US20200231693A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
SG11201900744SA (en) Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201805532XA (en) Multivalent and multispecific 41bb-binding fusion proteins
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11202000105QA (en) Anti-cd166 antibodies and uses thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201909011PA (en) Niraparib compositions
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201903693QA (en) Polypeptide variants and uses thereof
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201908847TA (en) Apparatuses, systems and methods for imaging flow cytometry
SG11201810687SA (en) Serum albumin-binding fibronectin type iii domains
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201906961UA (en) Polypeptide variants and uses thereof
SG11201906959RA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201807677YA (en) Antibodies to cd40 with enhanced agonist activity